What began as a lovely morning abruptly ended with a confusing press release describing a new clinical trial for hepatitis C. It seemed less like a notification of a new drug trial and more like an instrument of marketing.....
A service of the U.S. National Institutes of Health
ClinicalTrials.gov: Hepatitis C - updated in the last 30 days
The HCV clinical trials on this page are not a complete list; to learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.
Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects
Tuesday, October 02, 2012, 9:00:00 AM
Condition: Chronic Hepatitis C Infection
Interventions: Drug: ACH-0143102; Drug: Ribavirin
Sponsors: Achillion Pharmaceuticals; Achillion Pharmaceuticals
Recruiting - verified October 2012
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Tuesday, October 02, 2012, 9:00:00 AM
Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified October 2012
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With HCV
Thursday, September 27, 2012, 9:00:00 AM
Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified October 2012
Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4
Thursday, September 13, 2012, 9:00:00 AM
Condition: Chronic Hepatitis C Virus
Intervention: Drug: Pegylated interferon alpha-2a
Sponsors: King Abdulaziz Medical City; King Abdulaziz Medical City
Recruiting - verified September 2012
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Wednesday, September 12, 2012, 9:00:00 AM
Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267
Sponsors: Abbott; Abbott
Recruiting - verified September 2012
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Wednesday, September 12, 2012, 9:00:00 AM
Conditions: Recurrent Chronic Hepatitis C Virus; Post Liver Transplant
Interventions: Drug: GS-7977; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Not yet recruiting - verified September 2012
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Wednesday, September 12, 2012, 9:00:00 AM
Conditions: Hepatitis C; Cirrhosis; Portal Hypertension; With or Without Liver Decompensation
Interventions: Drug: GS-7977; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Not yet recruiting - verified September 2012
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Wednesday, September 05, 2012, 9:00:00 AM
Condition: Hepatitis C
Interventions: Drug: GS-7977 + RBV; Drug: GS-7977 placebo + RBV placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified October 2012
No comments:
Post a Comment